期刊文献+

益心舒胶囊治疗舒张性心力衰竭对IL-33/ST2信号通路的影响 被引量:2

下载PDF
导出
摘要 ST2是白介素-1受体(IL-1R)家族的成员之一,在体内存在的方式有跨细胞膜ST2受体及可溶性ST2两种。ST2的配体为IL-33,IL-33/ST2作为一个细胞内信号传导系统,参加到诸如抗原抗体反应,器官纤维化和心脏损伤等一系列病理变化中。研究表明IL-33激活ST2信号通路后,可导致心肌肥大、纤维化及心室功能不全,
机构地区 浙江省中医院
出处 《浙江中医杂志》 2015年第10期776-777,共2页 Zhejiang Journal of Traditional Chinese Medicine
基金 浙江省中医药科技计划项目IL-33/ST2信号在舒张性心力衰竭中的作用及益心舒联合比索洛尔的干预实验研究 编号:2012ZB033
  • 相关文献

参考文献8

  • 1Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of st2 protein in human hypertrophy and failure is re- lated to diastolic load [J].Journal of the American College of Car- diology. 2008,52 .. 2166-2174.
  • 2Shah RV,Januzzi JL,Jr.St2 :A novel remodeling biomarker in acute and chronic heart failure [J].Current heart failure reports. 2010,7..9-14.
  • 3Nishio M, Sakata Y, Mano T, et al. Beneficial effects of biso- prolol on the survival of hypertensive diastolic heart failure model rats [J].European journal of heart failure.2008 ; 10 .. 446-453.
  • 4周跃华,徐得生,冯怡.麦科提取物对小鼠营养血流量的影响[J].中国实验方刘学杂志,2000,9(31):22.
  • 5邢桂平,聂秀敏.黄芪注射液对充血性心力衰竭患者血流动力学的影响[J].中国医药导报,2006,3(11):67-68. 被引量:9
  • 6Rehman SU, Mueller T, Januzzi JL, Jr. Characteristics of the novel interleukin family biomarker st2 in patients with acute heart failure [J].Journal of the American College of Cardiology. 2008,52 .. 1458-1465.
  • 7Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Use- fulness of soluble concentrations of interleukin family member st2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction [J].The American journal of cardiology. 2011,107 : 259-267.
  • 8Seki K, Sanada S, Kudinova AY, et al.Interleukin-33 prevents apoptosis and improves survival after experimental myocardial in- farction through st2 signaling [J]. Circulation. Heart failure. 2009,2..684-691.

二级参考文献3

  • 1陈灏珠.实用内科学.止痛剂肾病(第10版)[M].北京:人民卫生出版社,1997.1852.
  • 2[1]The criteria committee of the Mew York Heart Association.Momenclature criteria of diagnosis disease of the heart and great vessel[m].6thrid.little Brown co,1964:114
  • 3包祥宁.黄芪注射液治疗老年充血性心衰[J].中药药理与临床,1999,15(6):39-40. 被引量:48

共引文献8

同被引文献35

  • 1Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammato-ry markers and incident heart failure risk in older adults= the Health ABC (Health, Aging,and Body Composition) study[J].J Am Coil Cardiol,2010,55(19) :2129-2137.
  • 2Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure:implication on interpretation of test results[J]. Am Heart J,2013,165(6) :995-999.
  • 3Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis[J]. Proc Natl Acad Sci U S A,2006,103(18):5060-5065.
  • 4Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turn- over in heart failure patients[J]. Clin Chim Acta,2009,409(1/2) : 96-99.
  • 5Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure:data from the DEAL-HF study[J]. Clin Res Cardiol, 2010,99 (5) : 323-328.
  • 6Yu L,Ruifrok WP, Meissner M, et al. Genetic and pharmacologi cal inhibition of galectin-3 prevents cardiac remodeling by interfer ing with myocardial fibrogenesis[J]. Circ Heart Fail, 2013,6 ( 1 ) 107-117.
  • 7Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 ceomprise a eritieal biomeehanieally indueed and eardiopmteetive signaling system[J]. J Clin Invest,2007,117(6) :1538-1549.
  • 8Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure ther- apy-induced early ST2 changes May offer long-term therapy guid- ance[J]. Card Fail,2013,19(12) :821-828.
  • 9闫洪光,韩锋.福辛普利与比索洛尔联合治疗舒张性心力衰竭的疗效分析[J].吉林医学,2012,33(15):3222-3223. 被引量:2
  • 10王靓,侯晓燕,黄金玲,王桐生,保永亮,施慧.苓桂术甘汤对慢性心衰模型大鼠心肌组织TNF-α及血清NF-κB和IL-1β的影响[J].中草药,2013,44(5):586-589. 被引量:56

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部